How Covid-19 kills and why it matters. The human body is

New Post Public Reply Private Reply Replies (2) Message Board
CTMedic
811
How Covid-19 kills and why it matters.

The human body is attacked by viruses every second of every day. There are over 380 trillion viruses in the human body and we inhale over 100 million every day. So how do any of us stay alive? It is a bit complicated.

Viruses themselves are not technically alive. In fact, outside of an infected cell, a virus is technically known as a virion and does nothing, but virus will do for this discussion. The virus is a collection of nucleic acids (RNA or DNA), surrounded by a protein coat, waiting to enter a host cell. Once inside the cell the virus becomes “alive” and those nucleic acids act a new set of instructions, directing the cell to make more viruses. When enough viruses are produced, the host cell ruptures, releasing the viruses to spread to next cell.

How do viruses enter the cell and how do they know which cell to enter? The virus really doesn’t know anything. The protein shell contains the nucleic acids, but also acts as a “key”, allowing entry to some cells, but not others. Sometimes this occurs through the fusion of the viral protein coat with the cell membrane, but more often viruses enter through cell membrane receptors. Receptors are doorways through the cell membrane, allowing signals to be received by the cell and desired substances to move in and out.

In Covid-19 disease, the SARS-CoV-2 virus enters epithelial cells of the lungs through the ACE-2 membrane receptor. Once inside, viral replication occurs, creating many more viruses and killing the epithelial cell. Left unchecked the virus kills millions of epithelial cells, damaging the lungs and causing shortness of breath.

However, the body does not take this attack lying down. The innate immune system (the immediate, non-specific immune system) has a number of infection fighting components that respond to an infection, even if the infecting virus has never been seen before. Damage-associated pattern recognition receptors recognize patterns associated with damage to infected cells and pathogen associated molecular pattern receptors recognize viruses (looks like a duck, quacks like a duck = some new kind of duck). Both receptors induce inflammatory cytokine release, activating an immune response.

In response, non-specific immune cells move to areas of cellular damage and inflammation. Natural killer cells destroy infected cells, slowing viral reproduction. Macrophages ingest and destroy viruses. Importantly, the macrophages present antigens, portions of the virus with a recognizable pattern, to T and B-lymphocytes. These lymphocytes learn to recognize the virus and are key components of the adaptive immune system. They antigen specific cells are the basis of targeted the acquired immune system (is supposed) to take over the immune response after the first 3-4 days of infection.

T lymphocytes recognize and bind to the virally infected cells. This is more specific than natural killer cells and continues after natural killer cells are exhausted. B-lymphocytes learn to recognize the virus and then replicate, with their offspring becoming plasma cells, which produce antibodies to the virus. The antibody binds to virus and marks it for destruction by a chemical cascade or ingestion by macrophages.

Vaccines target these same T and B-lymphocytes, “priming” the adaptive immune system by presenting antigens so that a vigorous, pathogen specific response is ready when exposure occurs.

So how does this process fail and why does it matter?

SARS-CoV-2 appears able to evade the innate immune system, delaying an immune response. Preventing the immune system from sounding the alarm has devastating consequences. The innate immune system, when finally activated, over responds. The activation of the more targeted adaptive immune system is delayed. The virus is allowed to reproduce nearly unchecked. Once the innate immune system “catches up”, the response is overwhelming, disproportionate and ultimately damaging to the patient.

In many or most infected patients, the immune system responds sufficiently quickly and effectively, so that patients are minimally or even asymptomatic. When the immune system does not respond appropriately, we see classic symptoms of severe Covid-19.

Late and overwhelming innate immune response induces the “cytokine storm”. So what is it and why does it matter? When the cytokine storm occurs, all manner of bad things happen. This is why so many Covid-19 patients present will bizarre and often unexpected symptoms.

The human body operates in is kept alive in a narrow range of conditions. Temperature 95-100. Too cold, the patient becomes confused, bleeds spontaneously, suffers cardiac arrhythmias and dies. Too hot and proteins denature, the brain cooks, the patient dies. The same limits exist for pH, oxygen level, fluid balance, electrolyte levels and so forth.

The same is true of the immune system. Too little activity, viruses, bacteria and fungi kill. Too much immune activity and the body attacks itself (lupus, rheumatoid arthritis, Sjogren’s and presumably Parkinson’s, Alzheimer’s, etc). A malfunctioning immune system affects other systems, most importantly the blood clotting system.

The principal symptoms of severe Covid-19 disease are due to dysregulation of the innate immune system and a malfunctioning clotting system.

The excess immune activation and cell trafficking fills the lungs a cesspool of excess immune cells and dying epithelial cells. Not good for pulmonary function.

The clotting system is delicate balance of pro-clotting and anti-clotting mechanisms. Too much clotting, we have strokes, heart attacks, pulmonary embolisms and we die. Too little clotting, we bleed precipitously and we die. The inflammation of the cytokine storm in Covid-19 impairs production of anticoagulant factors that keep the clotting system in balance, leading to “sticky” blood and microthrombosis (multiple diffuse blood clots).


So we have blood clots in bad places, an immune system off the rails. and junk in the lungs. This is obviously not good. However, given the opportunity, the body has mechanisms to fix most of what has gone wrong. Autopsies of Covid-19 patients in New York demonstrated wide spread clots in the lungs, but also extensive angiogenesis, the formation of new blood vessels to replace damaged vessels.

What needs to be done?

Stop the cytokine storm, restore the immune system and allow the body to heal itself.

How is that achieved?

Leronlimab

Leronlimab is a monoclonal antibody that binds to and occupies the CCR5 receptor, stopping the response of immune cells to an important cytokine, the chemotaxic cytokine (chemokine) CCL5/RANTES.

As has been discussed widely, blocking RANTES:

Stops the cytokine storm. Macrophages, natural killer and other immune cells stop trafficking to areas of infection, removing additional fuel from the fire and stopping the vicious circle of inflammation.

Macrophages repolarize from a pro-inflammatory state to normal state, so that they ingest and destroy viruses, as well as continuing to teach B and T how to recognize SARS-CoV-2.

Reverse immune exhaustion in existing T lymphocytes so that resume targeting and destroying virally infected cells.

Reverses cytokine-driven hypercoagulation and reduces the risk of new clot formation.

There are many therapeutics under development for Covid-19. Only one, Leronlimab stops the cytokine storm. Not just one cytokine, not just one symptom, the whole inflammatory pathway and resultant syndrome.

The more quickly the medical and regulatory communities recognize this, the sooner we will stop the unnecessary deaths and disruption of lives and livelihoods worldwide. Let’s get on it.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Skyven's Heat Pump Sets New Steam Efficiency Benchmark

Updated Category News Views 3

The Efficiency Game-Changer in Industrial Steam Swinging in like a seasoned market shake-up is Skyven Technologies, raising eyebrows—and interest—by nailing a coefficient of performance (COP) of 8.0 for their Arcturus heat pump. You don't have to be a market wizard to know that's a big leap from the initial COP of 6.5. It's more than just numbers on a page; this...

Continue Reading
Ivonescimab Shows Strong Survival in Key Lung Cancer Trial

Updated Category News Views 0

New Frontiers in Lung Cancer Treatment Well, here's a story that rattles the cage in the oncology world. The name of the game is ivonescimab, Akeso’s latest move as they toss their hat into the already crowded yet pivotal lung cancer treatment ring. This isn't just some side hustle—they've got Phase III data pointin' straight north, figuratively casting a shadow over...

Continue Reading
Geek+ Spurs Growth with 35.5% Order Surge and New Model

Updated Category News Views 2

Unexpected Surge in Orders Drives Geek+ It looks like Geek+ isn't just playing around in the robotics sandbox anymore. They're delivering some serious results, reporting a 35.5% increase in new signed orders reaching a whopping RMB2.385 billion for the first half of 2026. That's not chump change, and it injects a healthy dose of optimism into their future performance...

Continue Reading
Art Ave Spurs Rebirth in Downtown DC: A Template for Revival

Updated Category News Views 0

Turning Streets into Art Galleries No one would have believed a stretch of DC's bureaucratic offices was about to morph into a vibrant destination worthy of major art aficionados. But here we are, tipping our hats to the Golden Triangle Business Improvement District (BID), who just snagged the IDA Downtown Achievement Award of Excellence for their Art Ave project. Not...

Continue Reading
PMI Foods Fuels Hunger Action Month with New Partnership

Updated Category News Views 2

Helping Families Put Food on the Table Out there in Utah's schoolyards, Parker Migliorini International (PMI Foods) is taking a tangible step against hunger, whipping out a $15,000 check to back the Utah Food Bank’s Mobile School Pantry initiative. This partnership kicks off in September, aligning with Hunger Action Month, a period dedicated to spotlighting food...

Continue Reading
Tradr's Bold Venture: Anthropic ETFs Ahead of IPO

Updated Category News Views 2

Why Tradr Is Diving Into Anthropic's Hype There's a whiff of anticipation in the air as Anthropic gears up for its much-anticipated IPO, and Tradr isn't sitting on its hands here. They've just filed for two ETFs—one long, one short—ahead of the big day. We're talking about ANTT and ANTZ, betting on leveraged and inverse plays on whatever whirlwind Anthropic's stock...

Continue Reading
California's Annual Recovery Happens Event Unites Community

Updated Category News Views 2

A Public Campaign for Recovery Awareness Anyone with a pulse on what's going on in the addiction recovery landscape knows the significance of events like Recovery Happens. It's not just another day in Sacramento; it's a rallying cry for change—a public affirmation that recovery is tangible and thriving. This isn't about showy gala dinners or fancy corporate events; it's...

Continue Reading
Wahl's Bold Move: The Baldscaper™ Revolution

Updated Category News Views 2

A Legacy of Grooming Innovation When Wahl, a brand that's been in the grooming game for over a century, decides to go all in on a new product, you better believe it's worth a look. Wahl's new Baldscaper™ isn't just another gadget in the grooming aisle—it's a statement. Going bald can be a bold choice, and with their latest unveil, Wahl seems to be rewarding every...

Continue Reading
Common Threads Takes Nutrition Education Digital in 2026

Updated Category News Views 4

Digitizing 23 Years of Nutrition Know-How Common Threads has been in the trenches for over two decades, teaching kids and families how to eat right and cook healthier meals. Now, the nonprofit's dragging its vast experience into the digital realm, rolling out a beefed-up version of its TEACH platform this September 15th. Through new certificate courses in Nutrition...

Continue Reading
York Space Systems Faces Class Action After IPO Issues

Updated Category News Views 1

What's Up with York Space Systems? Alright, let's dive straight into this unfolding drama. York Space Systems—fresh off their IPO in January 2026—is now neck-deep in a class action lawsuit courtesy of Robbins LLP. It's a heavy hitter for folks who put money into their stock under the assumption that it was as solid as a rock. Instead, there seems to be a soft...

Continue Reading

Top 5 Most Recently Viewed Articles

Tech Sector Gains Momentum as Market Reacts to Rate Cuts

Updated Category News Views 63

Market Overview: Modest Gains and Trader Optimism As the week kicks off, U.S. index futures are showing slight upticks, signaling that traders remain hopeful despite waning enthusiasm from the recent rate cuts. There's a growing expectation that the technology sector will support the market, especially with recent developments involving Intel Corp (NASDAQ: INTC)....

Continue Reading
BDA Strengthens Portfolio with Acquisition of Harper + Scott

Updated Category News Views 944

BDA Strengthens Portfolio with Acquisition of Harper + Scott Deal Grows BDA's Roster of Enterprise Customers, Unites Top Branded Merchandise Agencies Bensussen Deutsch & Associates, LLC (BDA), the nation's leading Merchandise Agency™ for iconic brands including Major League Baseball, Johnson & Johnson, and The Home Depot, has acquired Harper + Scott, a creative branded...

Continue Reading
Mexco Energy Corporation Achieves Growth Amid Oil Price Challenges

Updated Category News Views 170

Mexco Energy Corporation Reports Impressive Financial Performance Mexco Energy Corporation (NYSE American: MXC), based in Midland, Texas, has reported notable financial results for the recently concluded six-month period. The company has achieved a net income of $565,457, translating to $0.27 per diluted share for the interim period ending September 30. Operating Revenues...

Continue Reading
Exciting Developments in (Z)-Endoxifen Research at SABCS 2025

Updated Category News Views 167

Atossa Therapeutics' Bold Moves in Breast Cancer Treatment Atossa Therapeutics, Inc. (NASDAQ: ATOS) is making waves in the oncology sector, focusing on innovative therapies for breast cancer. The company has recently announced that four abstracts on (Z)-endoxifen have been accepted for presentation at the renowned San Antonio Breast Cancer Symposium (SABCS), scheduled for...

Continue Reading
JPMorgan Global Growth & Income Adds New Ordinary Shares

Updated Category News Views 202

JPMorgan Global Growth & Income Expands Share Capital Recently, JPMorgan Global Growth & Income Plc took an important step by issuing 100,000 new Ordinary Shares priced at 581.70 pence each. This decision to issue additional shares aligns with the company’s ongoing strategy to enhance its operational capacity and foster growth. Impact on Share Capital This issuance has...

Continue Reading